@FootmaxAfter some of your previous posts, I've been looking at and discussing BIT relative's relative efficacy performance based on criteria as presented in prelims, Your suggestion that they're not good enough or we need finals to be better appears flawed mate. I'm assuming its just prior bias, unresearched. I now believe MM's saying they're good & MM is suggesting new class of drug is because they are genuinely good.
I've also had support for my theory that our efficacy results will potentially improve with time. Not able to ascertain cure or not as yet, but it would appear we likely "be clearin'"
Also had a closer look at the safety outcomes from 009 - not much in that to be of concern imo. Some Pyrexia etc. Good safety for 010's so far.
Also in the viroporin space, appears there's 2 on the NASADAQ, neither doing HIV. Were well ahead.
I was looking at NVIDIA chart in light of announcement tonight. Look how that went vertical once it hit the limelight. Question here is when do we imo.
Sure if you get an extra few shares by buying a little cheaper (if that's your play?) and hold them like NVIDIA, I guess its worth it, but on the other side not worth missing a position here imo.
SO not sure where you get the concerned line of thinking from .. any references?
Just FYI, DYOR.
